Genomics plc and GSK have initiated a collaborative endeavor to harness the potential of polygenic risk scores (PRS) in clinical trials, aiming to enhance comprehension of disease risk and refine patient selection, ultimately optimizing trial design and expediting drug development. Genomics plc, distinguished for its expertise in PRS-powered technologies, boasts comprehensive genetic databases and advanced algorithms dedicated to unraveling the genetic intricacies of diseases.
This partnership will explore diverse applications of Genomics’ PRS-powered tools, including their capacity to streamline trial participant selection, potentially reducing trial sizes, shortening study durations, and improving overall trial outcomes. Professor Sir Peter Donnelly, the Founder and CEO of Genomics plc, expressed excitement about the collaboration, highlighting the transformative potential of PRS-based approaches in revolutionizing clinical trial design and bolstering drug development efficiency.
Genetic factors exert profound influence on disease susceptibility, progression, and treatment response, often manifested through PRS—a composite measure of thousands of genetic variations. The collaboration aims to leverage PRS-based methodologies to facilitate patient selection, with a primary focus on minimizing patient recruitment numbers and accelerating trial timelines.
Robert Scott, the VP of Human Genetics and Genomics at GSK, commended Genomics plc for its leadership in developing and deploying PRS-based technologies, emphasizing the pivotal role of PRS in guiding clinical trial design and optimizing drug development processes.
Founded in 2014 by Professor Sir Peter Donnelly and colleagues from the University of Oxford, Genomics plc has established itself as a pioneering force in genomic medicine. With a workforce spanning the UK and the US, the company is dedicated to advancing healthcare through prevention-first approaches and personalized treatment pathways. Armed with a robust data platform and state-of-the-art analytical tools, Genomics plc leads the forefront of PRS-powered technology, offering risk prediction tools for tailored screening, diagnosis, and treatment. Moreover, the company supports drug discovery, clinical trial optimization, and companion diagnostic development across the life sciences sector.